Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 29, Issue 22, 2011, Pages 2965-2971

  Lara Jr , Primo N ^a   Douillard, Jean Yves ^b   Nakagawa, Kazuhiko ^c   Von Pawel, Joachim ^g   McKeage, Mark J ^d   Albert, Istvan ^e   Losonczy, Gyor̈gy ^f   Reck, Martin ^h   Heo, Dae Seog ⁱ   Fan, Xiaolin ^j   Fandi, Abderrahim ^j   Scagliotti Jr , Giorgio ^k  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CENTRE RENÉ GAUDUCHEAU   (France)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

^e Pulmonológiai Rehabilitációs Osztály   (Hungary)

^f SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^g ASKLEPIOS FACHKLINIKEN MÜNCHEN GAUTING   (Germany)

^h KRANKENHAUS GROSSHANSDORF   (Germany)

ⁱ The Catholic University of Korea   (South Korea)

^j NOVARTIS PHARMA AG   (Switzerland)

^k UNIVERSITY OF TURIN   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; VADIMEZAN; 5,6 DIMETHYLXANTHENONEACETIC ACID; 5,6-DIMETHYLXANTHENONEACETIC ACID; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; XANTHONE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSPNEA; FATIGUE; FEMALE; FEVER; HISTOPATHOLOGY; HUMAN; INJECTION SITE PAIN; INSOMNIA; LEUKOPENIA; LIMB PAIN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; NEUTROPENIA; NONCARDIAC CHEST PAIN; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; SENSORY NEUROPATHY; THROMBOCYTOPENIA; VOMITING; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; LUNG TUMOR; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; QUALITY OF LIFE; QUESTIONNAIRE; RISK; TREATMENT FAILURE;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; PACLITAXEL; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT FAILURE; XANTHONES;

EID: 80051638135     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.0660     Document Type: Article

References (18)

1. Thorpe PE: Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10:415-427, 2004
2. Huang X, Molema G, King S, et al: Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 227:547-550, 1997 (Pubitemid 27051913)
3. Liu JJ, Ching LM, Goldthorpe M, et al: Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours. Cancer Chemother Pharmacol 59:661-669, 2007 (Pubitemid 46295131)
4. Siemann DW: The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents. Cancer Treat Rev 37:63-74, 2011
5. McKeage MJ, Baguley BC: Disrupting established tumor blood vessels: An emerging therapeutic strategy for cancer. Cancer 116:1859-1871, 2010
6. Siim BG, Lee AE, Shalal-Zwain S, et al: Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 51:43-52, 2003 (Pubitemid 36057022)
7. McKeage MJ, von Pawel J, Reck M, et al: Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer 99:2006-2012, 2008
8. Schiller JH, Harrington D, Belani CP, et al: Comparison of 4 chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346:92-98, 2002 (Pubitemid 34438899)
9. Kelly K, Crowley J, Bunn PA, et al: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 19: 3210-3218, 2001 (Pubitemid 32591438)
10. McKeage MJ, Reck M, Jameson MB, et al: Phase II study of ASA404 (vadimezan, 5,6- dimethylxanthenone-4-acetic acid/DMXAA) 1800 mg/m2 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Lung Cancer 65:192-197, 2009
11. American Joint Committee on Cancer: AJCC Cancer Staging Handbook (ed 6). New York, NY, Springer-Verlag, 2002
12. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-smallcell lung cancer. N Engl J Med 355:2542-2550, 2006 (Pubitemid 44917502)
13. Pirker R, Pereira J, Szczesna A: Cetuximab plus chemotherapy in patients with advanced nonsmall- cell lung cancer (FLEX): An open-label randomised phase III trial. Lancet 373:1525-1531, 2009
14. Wilcox R, Djulbegovic B, Guyatt GH, et al: Randomized trials in oncology stopped early for benefit. J Clin Oncol 26:18-19, 2008
15. Chee KG, Nguyen D, Brown M, et al: Positron emission tomography and improved survival in patients with lung cancer: The Will Rogers phenomenon revisited. Arch Intern Med 168:1541-1549, 2008
16. Gandara DR, Kawaguchi T, Crowley J, et al: Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: A model for assessing population-related pharmacogenomics. J Clin Oncol 27:3540-3546, 2009
17. Gridelli C, Rossi A, Maione P, et al: Vascular disrupting agents: A novel mechanism of action in the battle against non-small cell lung cancer. The Oncologist 14:612-620, 2009
18. Garon EB, Kabbinavar F, Neidhart JA, et al: Randomized phase II trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P), and bevacizumab (B) in stage IIIb/IV nonsquamous non-small cell lung cancer (NSCLC): The FALCON trial. J Clin Oncol 28:559s, 2010 (suppl; abstr 7587)